U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata ...Middle East

PR Newswire - News
U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
LEQSELVI delivered statistically significant efficacy across two Phase 3 clinical trials. At baseline, the average patient had only 13% scalp hair coverage. At week 24, one-third of those patients experienced 80% scalp hair coverage. MUMBAI, India and PRINCETON, N.J., July 25, 2024...

Hence then, the article about u s fda approves leqselvi deuruxolitinib an oral jak inhibitor for the treatment of severe alopecia areata was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( U.S. FDA Approves LEQSELVI™ (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata )

Apple Storegoogle play

Last updated :

Also on site :